Immix Biopharma Expands US Nexicart-2 Trial for AL Amyloidosis With 3 Clinical Sites

MT Newswires Live08-28

Immix Biopharma (IMMX) on Wednesday announced the inclusion of three more clinical trial sites in the US for its Nexicart-2 trial on relapsed/refractory AL amyloidosis.

The newly added locations including Cleveland Clinic, UC Davis, and Sutter Health, feature some of the leading AL amyloidosis programs globally, broadening patient access to CAR-T NXC-201 across the US.

The Nexicart-2 trial aims to assess the safety and effectiveness of CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients with sufficient cardiac function who have not previously received BCMA-targeted therapy, the company said.

Shares of Immix Biopharma were up nearly 10% in recent trading.

Price: 2.40, Change: +0.22, Percent Change: +9.86

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2462648164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-28 22:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2462648164","market":"nz","top_or_hot":-1,"title":"Immix Biopharma Expands US Nexicart-2 Trial for AL Amyloidosis With 3 Clinical Sites","media":"MT Newswires Live","content":"<html><body><p> Immix Biopharma (IMMX) on Wednesday announced the inclusion of three more clinical trial sites in the US for its Nexicart-2 trial on relapsed/refractory AL amyloidosis.</p><p>The newly added locations including Cleveland Clinic, UC Davis, and Sutter Health, feature some of the leading AL amyloidosis programs globally, broadening patient access to CAR-T NXC-201 across the US.</p><p>The Nexicart-2 trial aims to assess the safety and effectiveness of CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients with sufficient cardiac function who have not previously received BCMA-targeted therapy, the company said.</p><p>Shares of Immix Biopharma were up nearly 10% in recent trading.</p><p>Price: 2.40, Change: +0.22, Percent Change: +9.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immix Biopharma Expands US Nexicart-2 Trial for AL Amyloidosis With 3 Clinical Sites</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmix Biopharma Expands US Nexicart-2 Trial for AL Amyloidosis With 3 Clinical Sites\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-28 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immix Biopharma (IMMX) on Wednesday announced the inclusion of three more clinical trial sites in the US for its Nexicart-2 trial on relapsed/refractory AL amyloidosis.The newly added locations ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AL","symbol_name":"航空租赁公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2462648164","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2462648164","pubTimestamp":1724855401,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immix Biopharma (IMMX) on Wednesday announced the inclusion of three more clinical trial sites in the US for its Nexicart-2 trial on relapsed/refractory AL amyloidosis.The newly added locations includ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AL":"航空租赁公司","BK4139":"生物科技","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","IMMX":"Immix Biopharma, Inc","BK4572":"航空租赁","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4104":"贸易公司与经销商"},"translate_title":"Immix Biopharma在3个临床站点扩大了针对AL淀粉样变性的美国Nexicart-2试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AL":1,"IMMX":0.9},"content_text":"Immix Biopharma (IMMX) on Wednesday announced the inclusion of three more clinical trial sites in the US for its Nexicart-2 trial on relapsed/refractory AL amyloidosis.The newly added locations including Cleveland Clinic, UC Davis, and Sutter Health, feature some of the leading AL amyloidosis programs globally, broadening patient access to CAR-T NXC-201 across the US.The Nexicart-2 trial aims to assess the safety and effectiveness of CAR-T NXC-201 in relapsed/refractory AL Amyloidosis patients with sufficient cardiac function who have not previously received BCMA-targeted therapy, the company said.Shares of Immix Biopharma were up nearly 10% in recent trading.Price: 2.40, Change: +0.22, Percent Change: +9.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2462648164"}